Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HY1272 · 1 trial · 1 indication
Incidence and severity of various adverse events, including physical examination, blood routine, blood biochemistry, urine flow sediment test, coagulation function, vital signs (pulse, respiration, blood pressure, body temperature), electrocardiogram, etc
Evaluate changes of Pharmacokinetics (PK) evaluation mainly Cmax from Week 1 to Week 3.
| Arm | Type | Description |
|---|---|---|
| HY1272 | EXPERIMENTAL | HY1272 IV weekly |
| Name | Type | Description |
|---|---|---|
| HY1272 | DRUG | Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily |
Inclusion Criteria: 1. Provision of signed and dated written informed consent prior to any study-specific procedures, sampling, and analyses. If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss of benefit...
HY1272 is an investigational small molecule being developed for the treatment of NSCLC Stage IV, specifically in patients with locally advanced or metastatic EGFRm+ non-small cell lung cancer. It is also being studied in patients with locally advanced or metastatic solid tumors.
HY1272 is being developed by Genelux Corporation, a biopharmaceutical company traded on the stock exchange under the ticker symbol GNLX. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
HY1272 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness in patients.
HY1272 is being studied in a Phase 1 clinical trial with the identifier NCT06218940. This trial is titled 'HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC' and is currently not yet recruiting participants.
The specific molecular target of HY1272 has not been disclosed in available information. As a small molecule, it is designed to interact with cellular components to exert its therapeutic effect, but the exact mechanism of action is not publicly detailed at this time.